Director Brown Jeffrey J was granted 12,177 shares, increasing direct ownership by 211% to 17,961 units (SEC Form 4)

$MED
Packaged Foods
Consumer Staples
Get the next $MED alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BROWN JEFFREY J

(Last) (First) (Middle)
C/O MEDIFAST, INC.
100 INTERNATIONAL DRIVE

(Street)
BALTIMORE MD 21202

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MEDIFAST INC [ MED ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2024 A 6,596(1) A $0 12,379.647 D
Common Stock 06/20/2024 A 5,581(2) A $22.66(3) 17,960.647 D
Common Stock 4,232.967 I Jeffrey Brown Living Trust(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. 6,596 restricted stock units were granted under the Medifast, Inc. Director's Deferred Compensation Plan, as Amended and Restated (the "Plan"), in connection with the payment of the reporting person's annual director fees. Each unit represents the right to receive one share of the Issuer's common stock. These awards are granted from the Issuer's 2012 Share Incentive Plan and will vest in full on June 20, 2025.
2. The reporting person elected, pursuant to the Plan, to receive shares of the Issuer's common stock in lieu of cash compensation for annual service as a non-employee director of the Issuer.
3. This price per share of $22.66 is based on the 20-day moving average stock price of the Issuer's common stock as of June 18, 2024.
4. These shares are directly owned by Jeffrey Brown Living Trust, for which the reporting person is the sole trustee and sole beneficiary.
Remarks:
/s/ Jason L. Groves, attorney-in-fact 06/24/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $MED alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MED

DatePrice TargetRatingAnalyst
11/5/2024$16.50 → $17.00Underperform → Neutral
DA Davidson
6/5/2024$25.00 → $17.50Neutral → Underperform
DA Davidson
10/13/2023$82.00Equal-Weight
Stephens
11/4/2022$278.00 → $106.00Buy → Neutral
DA Davidson
8/4/2022$345.00 → $150.00Buy → Hold
Jefferies
2/24/2022$349.00 → $341.00Buy
DA Davidson
11/8/2021$395.00 → $349.00Buy
DA Davidson
More analyst ratings

$MED
Press Releases

Fastest customizable press release news feed in the world

See more
  • Medifast Announces Fourth Quarter and Full Year 2024 Financial Results

    Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Revenue of $119.0 million, with revenue per active earning coach of $4,391 Independent active earning OPTAVIA coaches of 27,100 Net income of $0.8 million (non-GAAP adjusted net income of $1.1 million) Earnings per diluted share ("EPS") of $0.07 (non-GAAP adjusted EPS of $0.10) Cash, Cash Equivalents, and Investment Securities of $162.3 million and no debt Full Year 2024 Revenue of $602.5 million Net income of $2.1 million (non-GAAP adjusted net i

    $LFMD
    $MED
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples
  • Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2024

    Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the fourth quarter and full year ended December 31, 2024 on Tuesday, February 18, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on February 18, 2025. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.Medif

    $LFMD
    $MED
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples
  • Medifast Survey Finds Majority of U.S. Adults Trying to Lose Weight Agree Lifestyle Changes Are Essential – Even with Weight Loss Medications

    While 8 out of 10 U.S. adults trying to lose weight are eager to reach their goal as soon as possible, they agree that weight loss is an ongoing process requiring consistent attention and effort* Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today shared findings from a recent independent survey. Commissioned by Medifast and conducted by the third-party market research firm Talker Research, the goal of the survey was to better understand American perceptions of weight loss medications and their role in health journeys, while also identifying areas where further support is necessary. The survey of 2,000 nation

    $LFMD
    $MED
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples

$MED
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MED
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$MED
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MED
SEC Filings

See more

$MED
Leadership Updates

Live Leadership Updates

See more
  • KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

    $ADTN
    $ALTR
    $ATNI
    $BMRN
    Telecommunications Equipment
    Utilities
    Computer Software: Prepackaged Software
    Technology
  • Medifast Appoints Steven Zenker as Vice President of Investor Relations

    BALTIMORE, March 2, 2023 /PRNewswire/ -- Medifast (NYSE:MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today announced it has named Steven Zenker as Vice President of Investor Relations. Mr. Zenker has over 30 years of investor relations, financial planning and analysis, communications, and investment management experience. He reports to Chief Financial Officer Jim Maloney and will lead the strategy and continued implementation of the company's investor relations program. "We are pleased to welcome Steven to the Medifast t

    $MED
    Packaged Foods
    Consumer Staples

$MED
Financials

Live finance-specific insights

See more
  • Medifast Announces Fourth Quarter and Full Year 2024 Financial Results

    Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Revenue of $119.0 million, with revenue per active earning coach of $4,391 Independent active earning OPTAVIA coaches of 27,100 Net income of $0.8 million (non-GAAP adjusted net income of $1.1 million) Earnings per diluted share ("EPS") of $0.07 (non-GAAP adjusted EPS of $0.10) Cash, Cash Equivalents, and Investment Securities of $162.3 million and no debt Full Year 2024 Revenue of $602.5 million Net income of $2.1 million (non-GAAP adjusted net i

    $LFMD
    $MED
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples
  • Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2024

    Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the fourth quarter and full year ended December 31, 2024 on Tuesday, February 18, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on February 18, 2025. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.Medif

    $LFMD
    $MED
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples
  • Medifast Announces Third Quarter 2024 Financial Results

    Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672 Independent active earning OPTAVIA coaches of 30,000 Net income of $1.1 million (non-GAAP adjusted net income of $3.9 million) Income per diluted share of $0.10 (non-GAAP adjusted earnings per share ("EPS") of $0.35) Cash, Cash Equivalents, and Investment Securities of $170.0 million with no debt "Medical innovation has transformed the weight loss industry, so at Medifast we're creating a hea

    $LFMD
    $MED
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples

$MED
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more